Nycomed provides medicines and products for hospitals, specialists and general practitioners, as well as OTC medicines in selected markets. The company is active within a range of therapeutic areas, including gastroenterology, inflammation and pain, neurology, tissue management, respiratory and cardiology. In January 2007, Nycomed moved into its new corporate headquarters (HQ) in Zurich, Switzerland, with the company's HQ function now officially transferred from Denmark to Switzerland.

The acquisition of Altana Pharma at the end of 2006 was a huge milestone for Nycomed. To put it into context, combined sales of the pantoprazole franchise by the two companies in 2006 was nearly double the total company revenue of Nycomed during the same period. Consequently, fiscal 2007 is expected to be a landmark year for Nycomed, with sales of major products approaching EUR 2 billion. However, this rapid growth will not be sustained due to the loss of patent protection for pantoprazole throughout 2009 and 2010. Nycomed concedes that there is a gap in its clinical development, and without extensive in-licensing, the company can expect a rapid decline of sales within our forecast period.

The future for Nycomed's product portfolio appears to be within the respiratory field. Both Alvesco and Daxas are forecast to have sales in excess of EUR 500 million, and both could potentially peak at over EUR 1 billion. However, these products are competing in an extremely congested market and Nycomed will need to utilise its extensive marketing expertise throughout Europe to ensure strong sales.

Fiscal 2007 will be a year of integration and re-organisation for Nycomed. The company can be confident of significantly increased revenues, but in order for this to be sustained beyond the patent expiry of pantoprazole, Nycomed will need to rapidly utilise the infrastructure and expertise it has gained from Altana Pharma to ensure the long-term success of the company.

Latest Results
Executive Summary
- Introduction
- Current Financial Position
  - Company Performance
  - Business Segment Performance
  - Geographic Segment Performance
- Company Strategy
  - Mergers, Acquisitions and Divestitures
  - Key Agreements
    - Discontinued Agreements
  - Employees
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions
Therapeutic Area Focus
R&d Pipeline
Gastroenterology
- Marketed Products
  - Pantozol
R&d Projects
- Growth Forecast
Inflammation
- Marketed Products
  - Calcichew
  - Preotact
- Growth Forecast
Pain
- Marketed Products
  - Matrifen
  - Xefo
  - Others
- R&D Projects
  - Instanyl
  - Posidur
- Growth Forecast
Respiratory
- Marketed Products
  - Alvesco
  - Others
- R&D Projects
  - Daxas
  - Venticute
- Growth Forecast
Others
- Marketed Products
- R&D Projects
  - TransMID
Appendix 1 - Financial Performance
- Full Year Results 2006
Appendix 2 - Key Corporate Events
- Nycomed
- Altana Pharma
Appendix 3 - Key Agreements
- Abbott
- Acusphere Inc
- Bayer
- BioPartners GmBH
- CeNeS Pharmaceuticals Ltd
- Durect Corporation
- Hua Wei
- Ks Biomedix Holdings
- Merck KGaA
- Micromet Inc
- Mitsubishi Tanabe Pharma Corporation
- Novartis
- Nps Pharmaceuticals Inc
- Paladin Labs Inc
- Pfizer
- Pozen Inc
- Protherics plc
- Recordati
- sanofi-aventis
- Sepracor Inc
- Teijin Limited
- Wyeth
Appendix 4 - Infrastructure
- Research and Development Facilities
- Manufacturing Facilities
Appendix 5 - Key Pharmaceutical
Subsidiaries / Joint Ventures
- Subsidiaries
- Joint Ventures
Index of Tables
- Principal Operating Results
- Sales by Region
- Operating Profit by Region
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Gastroenterology Products, 2006
- Major Inflammation Products, 2006
- Major Pain Products, 2006
- Major Respiratory Products, 2006
- Major Other Products, 2006
  - Nycomed
Index of Charts
- Year of Foundation: 1874
- Sales by Region
- Operating Profit by Region
- Sales of Major Products (2004A-2011E)
- Top Selling Products, 2006
- Pantozal Sales (2001A-2011E)
- Calcichew Sales (2001A-2011E)
- Preotact Sales (2001A-2011E)
- Matrifen Sales (2001A-2011E)
- Xefo Sales (2001A-2011E)
- Naf Sales (2009e-2013e)
- Alvesco Sales (2001A-2011E)
- Daxas Sales (2009E-2013E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity

Pharmaceutical Market Research

Nycomed

Nycomed

Contents

Related products